Seller record · Telehealth service

RENN Health

Fails 3 of 8 criteria. S4, compounding disclosure: The weight loss pages sell semaglutide and tirzepatide filled through the named partner pharmacies and never say whether the medication is compounded, and no page, including the answers, the terms and the privacy policy, states that it is not FDA-approved. 2 more criteria also fail; see the table below.

Telehealth service. Passes 5 of 8 criteria. Recorded against Standard v1.1.

A virtual practice serving all 50 states with semaglutide and tirzepatide weight loss plans, NAD+ therapy and testosterone replacement therapy on monthly subscriptions. Care starts with an online medical intake reviewed by a licensed provider, and it names six partner pharmacies but never says whether its GLP-1 medications are compounded.

Operating entity No legal entity name appears in the footer, in the terms and conditions, in the privacy policy, in the notice of privacy practices or in the telehealth consent, which name the business only as RENN Health.

Dispositions

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

Products shown on the seller's own pages at the recorded date: semaglutide, tirzepatide, NAD+ therapy, testosterone replacement therapy.

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.